Clinical trial for mesothelioma patients: Dasatinib (NSC # 732517) study description

Read the study description for a current clinical trial being conducted to study the effects of Dasatinib (NSC # 732517) for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Study Description

Phase, Type and Design: Phase II Interventional Study; Treatment, Open Label

Primary Outcome Measure: Progression-free survival (PFS) at 24 weeks (or 5.5 months)

Secondary Outcome Measure: Response rate (complete and partial response) as measured by RECIST criteria; Correlation of expression levels of EphA2 and PDGFRß with response, PFS, and overall survival Correlation of plasma levels of VEGF and PDGFRß, serum levels of CSF-1, and soluble mesothelin-related protein with response, PFS, and overall survival; Correlation of a decrease in Src phosphorylation in PBMC with response, PFS, and overall survival ; Correlation of a decrease in the phosphorylation of Src, EphA2, and PDGFRß in tumor tissue with response

Condition: Malignant Mesothelioma

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney